Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart risk from chemo: study stopped after just 2 patients

NCT ID NCT05803889

Knowledge-focused Sponsor: Institut de cancérologie Strasbourg Europe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to closely monitor heart function in women with breast cancer receiving common chemotherapy drugs (epirubicin, cyclophosphamide, paclitaxel) to see when heart damage first appears. Researchers planned to use advanced ultrasound and exercise tests to detect early changes. However, the study was terminated early with only 2 participants enrolled, so no meaningful conclusions could be drawn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2 people

The number who actually took part.

Started

Sep 2023

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Population composed of a group of breast cancer patients undergoing chemotherapy with EC and Tax, and a group of breath cancer patients undergoing Trastuzumab treatment.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Epirubicin-cyclophosphamide + paclitaxel group: * Female ≥ 18 years * Stage I to III breast cancer * Patient being planned for (neo)adjuvant therapy combining EC and Taxol on a weekly basis * Enrolled in a social security plan * Able to speak, read and understand French Trastuzumab group: * Female ≥ 18 years of age * Stage I to III breast cancer * Patient treated with trastuzumab * Enrolled in a social security plan * Able to speak, read and understand French Exclusion Criteria: For both groups: Epirubicin-cyclophosphamid + paclitaxel group and trastuzumab group * Implantation of a pacemaker * Contraindications to exercise * Protected adult * Psychiatric, musculoskeletal or neurological problems * Pregnant or breastfeeding woman * Uncontrolled high blood pressure * Body Mass Index \> 35 kg/m²

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Institut de cancérologie Strasbourg Europe

    Strasbourg, France, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.